Latest News for: vedotin
Edit
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) (Form 8-K) (BioAtla Inc)
Public Technologies 31 Dec 2025
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) • ... About Ozuriftamab Vedotin (Oz-V).
Edit
The Galveston Daily News
17 Dec 2025
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete ...
Edit
KEYTRUDA� (pembrolizumab) Plus Padcev� (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete ...
Business Wire 17 Dec 2025
The trial showed KEYTRUDA� (pembrolizumab) plus Padcev � (enfortumab vedotin-ejfv), given as ...
Edit
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
Pharmiweb 17 Dec 2025
“The strength of these data demonstrates that pembrolizumab plus enfortumab vedotin—given before and after surgery—has the potential to significantly improve survival outcomes.”.
Edit
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery (Merck & Co Inc)
Public Technologies 17 Dec 2025
"The strength of these data demonstrates that pembrolizumab plus enfortumab vedotin-given before and after surgery-has the potential to significantly improve survival outcomes.".
Edit
MHRA approves tisotumab vedotin for the treatment of cervical cancer (MHRA - Medicines and Healthcare products Regulatory Agency)
Public Technologies 02 Dec 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 2 December 2025, approved tisotumab vedotin (Tivdak) used for the treatment of adults with cervical cancer that has come back or spread.
Edit
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with Muscle-Invasive Bladder CancerCorporatePartnerships (Pfizer Inc)
Public Technologies 01 Dec 2025
) European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA™ (pembrolizumab) for Certain Patients with ...
- 1